• 沒有找到結果。

[PDF] Top 20 Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B

Has 10000 "Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B" found on our website. Below are the top 20 most common "Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B".

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B

... Adefovir dipivoxil (Hepsera, Gilead Sciences) is an oral prodrug of adefovir, a phosphonate nucleo- tide analogue of AMP with potent activity against the polymerase activity ... See full document

8

Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B

Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B

... t e r m a d e f o v i r t h e r a p y f o r c h r o n i c h e p a t i t i s b file over 144 weeks remained consistent with that seen earlier in the ...studies, treatment ... See full document

9

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

... with chronic hepatitis B, 48 weeks of treatment with adefovir dipivoxil resulted in signif- icant histologic improvement, reduced serum HBV DNA levels, and increased ... See full document

10

Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants

Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants

... assessing the durability of lamivudine-in- duced HBeAg seroconversion have suggested that longer treat- ment after seroconversion increased sustained ...months of additional lamivudine therapy ... See full document

7

Using Hepatitis B Surface Antigen Quantification to the Management of Hepatitis B

Using Hepatitis B Surface Antigen Quantification to the Management of Hepatitis B

... Assess HBsAg Positive CHB* Evaluate for treatment Negative Assess anti-HBs Negative.. (No antibodies) (Antibodies Positive present).[r] ... See full document

46

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B

... because of an alanine amino- transferase ...during treatment and were ob- served with similar frequencies in the two treat- ment groups (Table ...during treatment were observed in three ... See full document

10

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients

... reported the initial phase III study of Peg-IFN therapy in patients with HBeAg-negative CHB and demonstrated that 48 weeks of Peg-IFN Alfa-2a mono therapy achieved HBV DNA<400 and<20,000 ... See full document

28

Pegylated interferon alfa-2a therapy for HBeAg-negative chronic hepatitis B in Taiwan

Pegylated interferon alfa-2a therapy for HBeAg-negative chronic hepatitis B in Taiwan

... method: The aim of this study was to evaluate the efficacy and predictors of peg-INF alfa-2a therapy for HBeAg-negative chronic hepatitis B patients in ... See full document

1

Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis

Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis

... discontinuation of Nuc treatment can be considered after demonstration of undetectable serum HBV DNA on three separate occasions at least 6 months apart ...Given the findings of ... See full document

23

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study

... mg for the primary and key secondary virologic ...address the mixed nature of the study population demonstrated consistent findings across all groups assessed; therefore, our findings ... See full document

10

Chronic hepatitis B reactivation and systemic glucocorticosteroid therapy.

Chronic hepatitis B reactivation and systemic glucocorticosteroid therapy.

... of the patients had chronic HBV infection, but the incidence of severe hepatitis was found to be 53%, which was associated with a mortality rate of ...use of ... See full document

2

A Predictive Scoring System for the Seroclearance of HBsAg in HBeAg-seronegative Chronic Hepatitis B Patients with Genotype B or C Infection

A Predictive Scoring System for the Seroclearance of HBsAg in HBeAg-seronegative Chronic Hepatitis B Patients with Genotype B or C Infection

... Seroclearance of hepatitis B surface antigen (HBsAg) is the most ideal endpoint in the treatment of chronic hepatitis ...whether the addition ... See full document

27

Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B

Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B

... daily. Adefovir was not used in the first line but restricted in the rescue setting, per the regulation of the Taiwan National Health ...Insurance. For those who acquired ... See full document

25

Hepatitis B viral factors and treatment responses in chronic hepatitis B

Hepatitis B viral factors and treatment responses in chronic hepatitis B

... From the conventional IIR notch filters, we see that the IIR notch filters can be designed by a two-stage ...place the zeros on the unit circle with angles equal to notch frequen- cies such ... See full document

9

Hepatitis B virus mutants associated with hepatitis b surface antigen loss: Chicken or egg?

Hepatitis B virus mutants associated with hepatitis b surface antigen loss: Chicken or egg?

... The problems to be considered here are not only characterized by a weighted Hamming distance matrix D (as before) but also a cost vector C of all relevant process plans and [r] ... See full document

6

Hepatitis B virus with primary resistance to adefovir

Hepatitis B virus with primary resistance to adefovir

... h e n e w e n g l a n d j o u r n a l o f m e d i c i n e n engl j med 355;3 ...percent of lung volume) among those with a higher amount of potentially recruitable lung, ... See full document

2

Natural history of chronic hepatitis B REVEALed

Natural history of chronic hepatitis B REVEALed

... history of major diseases, dietary intake, as well as habits of cigarette smoking, alcohol consumption and betel nut ...on the day of collection and stored at -70°C until ...France). ... See full document

11

A pre-S gene chip to detect pre-S deletions in hepatitis B virus large surface antigen as a predictive marker for hepatoma risk in chronic hepatitis B virus carriers

A pre-S gene chip to detect pre-S deletions in hepatitis B virus large surface antigen as a predictive marker for hepatoma risk in chronic hepatitis B virus carriers

... in chronic HBV carriers usu- ally requires multiple experimental procedures, because most pre-S mutants co-exist with wild-type LHBS in blood and hepatocytes; this is probably due to the emergence of ... See full document

8

Chronic Hepatitis B Virus Infection and Dyslipidemia

Chronic Hepatitis B Virus Infection and Dyslipidemia

... using the methods of Paffenbarger et al, 12 and computed as an estimate of energy expended in walking, climbing stairs, playing sports, yard work, and so ...on the question- naire. Amount ... See full document

6

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B

... with hepatitis B e antigen (HBeAg)–positive chronic hepatitis B who had not previously received a nucleoside analogue to receive either ...mg of entecavir or 100 mg ... See full document

1

Show all 10000 documents...